Literature DB >> 15503196

The yield of laboratory investigations in children with infantile autism.

B Kosinovsky1, S Hermon, R Yoran-Hegesh, A Golomb, Y Senecky, H Goez, U Kramer.   

Abstract

PURPOSE: To evaluate the yield of laboratory investigations in infantile autism.
METHODS: We retrieved and evaluated the results of investigative procedures recorded in the medical files of autistic infants in four child developmental centers and two pediatric psychiatric outpatient clinics.
RESULTS: One-hundred and thirty-two infants were included in the study of whom 47 (36%) underwent autistic regression at an average age of 20 months. The investigative procedures included electroencephalogram (n = 132), neuroimaging (n = 70), genetic studies to detect Fragile-X (n = 59) and a metabolic workup (n = 53). Except for the molecular diagnosis that revealed Fragile-X syndrome in two children (3%), all other tests were negative. The two infants with the Fragile-X syndrome belonged to the non-regressive group.
CONCLUSIONS: The only investigative study that contributed to the diagnosis of autistic infants was the molecular diagnosis detecting Fragile-X. In spite of the high frequency of epilepsy and epileptiform abnormalities in the electroencephalograms of autistic children in general, the contribution of epilepsy, both clinical and subclinical, to the etiology of autism is apparently minimal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15503196     DOI: 10.1007/s00702-004-0198-8

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  8 in total

Review 1.  Epilepsy in autism spectrum disorders.

Authors:  Roberto Canitano
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-24       Impact factor: 4.785

2.  The relationship between brain abnormalities and autistic psychopathology in pervasive developmental disorders.

Authors:  Andrea Efremova; Jiri Lisy; Michal Hrdlicka
Journal:  J Appl Biomed       Date:  2021-04-14       Impact factor: 1.797

Review 3.  What's new in autism?

Authors:  Jean G Steyaert; Wouter De la Marche
Journal:  Eur J Pediatr       Date:  2008-07-03       Impact factor: 3.183

4.  Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.

Authors:  Craig A Erickson; Balmiki Ray; Bryan Maloney; Logan K Wink; Katherine Bowers; Tori L Schaefer; Christopher J McDougle; Deborah K Sokol; Debomoy K Lahiri
Journal:  J Psychiatr Res       Date:  2014-08-19       Impact factor: 4.791

5.  Should metabolic diseases be systematically screened in nonsyndromic autism spectrum disorders?

Authors:  Manuel Schiff; Jean-François Benoist; Sofiane Aïssaoui; Odile Boespflug-Tanguy; Odile Boepsflug-Tanguy; Marie-Christine Mouren; Hélène Ogier de Baulny; Richard Delorme
Journal:  PLoS One       Date:  2011-07-07       Impact factor: 3.240

6.  Peripheral Amyloid Precursor Protein Derivative Expression in Fragile X Syndrome.

Authors:  Richard D McLane; Lauren M Schmitt; Ernest V Pedapati; Rebecca C Shaffer; Kelli C Dominick; Paul S Horn; Christina Gross; Craig A Erickson
Journal:  Front Integr Neurosci       Date:  2019-09-03

7.  Screening for FMR1 CGG Repeat Expansion in Thai Patients with Autism Spectrum Disorder.

Authors:  Areerat Hnoonual; Charunee Jankittunpaiboon; Pornprot Limprasert
Journal:  Biomed Res Int       Date:  2021-12-08       Impact factor: 3.411

8.  Role of NAD(+), Oxidative Stress, and Tryptophan Metabolism in Autism Spectrum Disorders.

Authors:  Musthafa Mohamed Essa; Selvaraju Subash; Nady Braidy; Samir Al-Adawi; Chai K Lim; Tamilarasan Manivasagam; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2013-07-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.